{"transactions":[{"id":673932,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-08-27T20:34:59.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18353,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each outstanding restricted stock unit (a \"Company RSU\"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0001863614-26-000003","document":"form4-08272026_080854.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000186361426000003/form4-08272026_080854.xml","form_type":"4"}},{"id":673931,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:34:59.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.54,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001863614-26-000003","document":"form4-08272026_080854.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000186361426000003/form4-08272026_080854.xml","form_type":"4"}},{"id":673930,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:34:59.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":8.6,"exercise_date":"2025-05-29","expiration_date":"2034-08-20","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001863614-26-000003","document":"form4-08272026_080854.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000186361426000003/form4-08272026_080854.xml","form_type":"4"}},{"id":673929,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:34:59.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":20,"exercise_date":"2024-08-20","expiration_date":"2033-09-19","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001863614-26-000003","document":"form4-08272026_080854.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000186361426000003/form4-08272026_080854.xml","form_type":"4"}},{"id":673928,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-27T20:34:59.000Z","date":"2026-08-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the \"Merger Agreement\"), by and among Forte Biosciences, Inc. (\"Company\"), argenx BV (\"Parent\"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), each unexercised and outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share (\"Merger Consideration\"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":25,"exercise_date":"2025-11-10","expiration_date":"2032-11-10","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001863614-26-000003","document":"form4-08272026_080854.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000186361426000003/form4-08272026_080854.xml","form_type":"4"}},{"id":743288,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T22:51:18.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Corporation's stockholders."}],"balance_after":22000,"derivative":{"exercise_price":3.22,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001193125-26-266220","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000119312526266220/ownership.xml","form_type":"4"}},{"id":755097,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-02T20:36:04.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":18353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Forte Biosciences, Inc. (the \"Issuer\") Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person's continuing as a Service Provider (as defined in the 2021 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the date of the first annual meeting of the stockholders that occurs after May 29, 2026."}],"balance_after":18353,"derivative":{"underlying":"Common Stock","underlying_shares":18353},"source":{"system":"sec-edgar","filing":"0001863614-26-000002","document":"form4-06022026_080600.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000186361426000002/form4-06022026_080600.xml","form_type":"4"}},{"id":1092690,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T20:25:47.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders."}],"balance_after":7500,"derivative":{"exercise_price":6.77,"exercise_date":"2026-07-03","expiration_date":"2035-07-03","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-25-061503","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000121390025061503/ownership.xml","form_type":"4"}},{"id":1118114,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-10T00:22:15.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 9, 2026 or (ii) the date of the next annual meeting of the Corporation's stockholders."}],"balance_after":22000,"derivative":{"exercise_price":2.37,"expiration_date":"2035-06-08","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000950170-25-084019","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000095017025084019/ownership.xml","form_type":"4"}},{"id":1143002,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-20T01:44:32.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $1.92 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date.  Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\", through which the Reporting Person must remain in service to the Issuer, commenced on the Repricing Date and ends upon the earliest of (i) the one-year anniversary of the Repricing Date, (ii) a Sale Event (as defined in the 2018 Plan and 2019 Plan, as applicable) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2018 Plan and 2019 Plan, as applicable) due to the Reporting Person's death or disability."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 15, 2025, the Issuer's board of directors approved an option repricing (the \"Repricing\"), to be effective May 19, 2025 (the \"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan, as amended (the \"2018 Plan\") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, as amended (the \"2019 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":1.92,"expiration_date":"2034-06-02","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000950170-25-074832","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000095017025074832/ownership.xml","form_type":"4"}},{"id":1143001,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-20T01:44:32.000Z","date":"2025-05-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 15, 2025, the Issuer's board of directors approved an option repricing (the \"Repricing\"), to be effective May 19, 2025 (the \"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan, as amended (the \"2018 Plan\") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, as amended (the \"2019 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":10.01,"expiration_date":"2034-06-02","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000950170-25-074832","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000095017025074832/ownership.xml","form_type":"4"}},{"id":1143000,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-20T01:44:32.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $1.92 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date.  Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\", through which the Reporting Person must remain in service to the Issuer, commenced on the Repricing Date and ends upon the earliest of (i) the one-year anniversary of the Repricing Date, (ii) a Sale Event (as defined in the 2018 Plan and 2019 Plan, as applicable) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2018 Plan and 2019 Plan, as applicable) due to the Reporting Person's death or disability."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 15, 2025, the Issuer's board of directors approved an option repricing (the \"Repricing\"), to be effective May 19, 2025 (the \"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan, as amended (the \"2018 Plan\") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, as amended (the \"2019 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":22000,"derivative":{"exercise_price":1.92,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000950170-25-074832","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000095017025074832/ownership.xml","form_type":"4"}},{"id":1142999,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-20T01:44:32.000Z","date":"2025-05-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 15, 2025, the Issuer's board of directors approved an option repricing (the \"Repricing\"), to be effective May 19, 2025 (the \"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan, as amended (the \"2018 Plan\") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, as amended (the \"2019 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":11.18,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000950170-25-074832","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000095017025074832/ownership.xml","form_type":"4"}},{"id":1142998,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-20T01:44:32.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the option is $1.92 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date.  Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\", through which the Reporting Person must remain in service to the Issuer, commenced on the Repricing Date and ends upon the earliest of (i) the one-year anniversary of the Repricing Date, (ii) a Sale Event (as defined in the 2018 Plan and 2019 Plan, as applicable) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2018 Plan and 2019 Plan, as applicable) due to the Reporting Person's death or disability."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 15, 2025, the Issuer's board of directors approved an option repricing (the \"Repricing\"), to be effective May 19, 2025 (the \"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan, as amended (the \"2018 Plan\") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, as amended (the \"2019 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":44000,"derivative":{"exercise_price":1.92,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0000950170-25-074832","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000095017025074832/ownership.xml","form_type":"4"}},{"id":1142997,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-20T01:44:32.000Z","date":"2025-05-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 15, 2025, the Issuer's board of directors approved an option repricing (the \"Repricing\"), to be effective May 19, 2025 (the \"Repricing Date\"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan, as amended (the \"2018 Plan\") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, as amended (the \"2019 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":7.35,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0000950170-25-074832","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000095017025074832/ownership.xml","form_type":"4"}},{"id":1194736,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-03-21T20:46:35.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over a three (3) year period such that the option shall be fully vested on the third (3rd) anniversary of the Date of Grant.  \"Date of Grant\" shall mean March 20, 2025."}],"balance_after":31000,"derivative":{"exercise_price":7.54,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001415889-25-008781","document":"form4-03212025_080329.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000141588925008781/form4-03212025_080329.xml","form_type":"4"}},{"id":1425575,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-08-22T20:06:39.000Z","date":"2024-08-20","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. \"Date of Grant\" shall mean August 20, 2024."}],"balance_after":50000,"derivative":{"exercise_price":0.344,"expiration_date":"2034-08-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-24-021999","document":"form4-08222024_080836.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000141588924021999/form4-08222024_080836.xml","form_type":"4"}},{"id":1485163,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T22:17:19.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7500,"derivative":{"exercise_price":25.41,"exercise_date":"2025-06-06","expiration_date":"2034-06-06","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-24-051401","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000121390024051401/ownership.xml","form_type":"4"}},{"id":1492712,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T23:17:38.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 3, 2025 or (ii) the date of the next annual meeting of the Corporation's stockholders."}],"balance_after":22000,"derivative":{"exercise_price":10.01,"expiration_date":"2034-06-02","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000950170-24-068984","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000095017024068984/ownership.xml","form_type":"4"}},{"id":1776308,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-09-20T21:55:22.000Z","date":"2023-09-19","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. \"Date of Grant\" shall mean September 19, 2023."}],"balance_after":25000,"derivative":{"exercise_price":0.8,"expiration_date":"2033-09-19","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-050196","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000120919123050196/doc4.xml","form_type":"4"}},{"id":1849893,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-21T01:48:28.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":94000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on June 20, 2024, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":94000,"derivative":{"exercise_price":1.35,"expiration_date":"2033-06-20","underlying":"Voting Common Stock","underlying_shares":94000},"source":{"system":"sec-edgar","filing":"0001213900-23-050220","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000121390023050220/ownership.xml","form_type":"4"}},{"id":1870277,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-02T11:30:07.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 1, 2024 or (ii) the date of the next annual meeting of the Corporation's stockholders."}],"balance_after":22000,"derivative":{"exercise_price":11.18,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000899243-23-014330","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000089924323014330/doc4.xml","form_type":"4"}},{"id":2118196,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-11-14T21:22:06.000Z","date":"2022-11-10","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the thirty six (36) months following the Date of Grant, such that the shares subject to the option shall be fully vested on the third (3rd) anniversary of the Date of Grant. \"Date of Grant\" shall mean November 10, 2022."}],"balance_after":50000,"derivative":{"exercise_price":1,"expiration_date":"2032-11-10","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-22-056612","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000120919122056612/doc4.xml","form_type":"4"}},{"id":2245182,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T20:47:22.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (1) June 1, 2023 or (2) the date of the next annual meeting of the Corporation's stockholders."}],"balance_after":22000,"derivative":{"exercise_price":1.28,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000899243-22-020999","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000089924322020999/doc4.xml","form_type":"4"}},{"id":2653810,"issuer":{"id":5418,"kind":"organization","name":"Cabaletta Bio, Inc."},"owners":[{"id":19110,"kind":"person","name":"Brun Scott C.","position":1,"cik":"0001863614","reported_name":"Brun Scott C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-28T20:30:37.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Shares shall vest and become exercisable in 12 equal quarterly installments commencing on June 24, 2021, provided that the Reporting Person continues to have a Service Relationship with the Company on each vesting date."}],"balance_after":44000,"derivative":{"exercise_price":7.35,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0000899243-21-026198","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863614/000089924321026198/doc4.xml","form_type":"4"}}]}